Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lurbinectedin - PharmaMar

Drug Profile

Lurbinectedin - PharmaMar

Alternative Names: JZP-712; Lurbinectedina - PharmaMar; LY-01017; PM-01183; PM-1183; Tryptamicidin; Zepsyre; ZEPZELCA; Zepzelca

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaMar
  • Developer ADIUM PHARMA; Immedica; Jazz Pharmaceuticals plc; Luye Pharma Group; PharmaMar; Roche; Specialised Therapeutics Asia; Swiss Group for Clinical Cancer Research
  • Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Carbolines; Dioxolanes; Indoles; Small molecules; Spiro compounds; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Malignant-mesothelioma; Soft tissue sarcoma; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Phase III Ovarian cancer
  • Phase II/III Leiomyosarcoma
  • Phase II Breast cancer; Malignant-mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Phase I/II Ewing's sarcoma; Soft tissue sarcoma

Most Recent Events

  • 04 Jun 2024 Efficacy and adverse events data from the phase III LAGOON trial in Small cell lung cancer presented at the American Society of Clinical Oncology meeting (ASCO-2024)
  • 01 May 2024 Phase-III clinical trials in Small cell lung cancer (Monotherapy, Second-line therapy or greater) in Japan, Taiwan, Turkey (IV) (NCT05153239)
  • 01 May 2024 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Combination therapy) in Japan, Taiwan, Turkey (IV) (NCT05153239)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top